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ABSTRACT 
A review of cytotoxicity associated with cancer treatments as presented in literature was discussed. In all the studies, the research is 
aware of the cytotoxic effects of the cancer drug and the delivery form such as nanotechnology-based delivery. The scope of the 
review was limited to showing 1) the need for modulating cytotoxicity and 2) how cytotoxicity has been controlled in actual studies 
on treatment plans in vivo and in vitro.  
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Introduction 
Cytotoxicity is the action of a cytotoxic compound on a cell 
that the cell will either undergo necrosis by the loss of the 
integrity of their membrane, followed by its rapid death, or 
is guided to the pathway of apoptosis or autophagy1-5. 
Cytotoxic drugs or cytostatics are used for the treatment of 
cancer where they destroy the cancer-causing cells. By 
inhibiting cell division, this process of cell destruction is 
started. While cytotoxic drugs used to reduce metastases 
help control the spread of cancer and effectively act upon 
primary and secondary tumors, the drugs also have an 
effect on surrounding healthy cells6-12. Effect on normal 
cells is less pronounced compared to cancer cells, and yet 
in the case of aggressive tumor conditions, the effect on 
normal cells is also higher, either killing them or 
necessitating more time for the healthy cells to recover. In 
this context, research works aim to identify how cancer can 
be treated by controlling cytotoxicity. This work reviews 
the effects of modulating cytotoxicity effects in cancer drug 
delivery by looking up research works on the same13-19.  
Cytotoxicity and Treatment Efficacy 
The use of nano-technology based medication delivery has 
been heralded as an optimal solution for cancer treatment. 
However, cytotoxicity has to be banked against efficacy. 
The drug that cures should not be the drug that also 
induces a new issue. All nanomedicines have some amount 
of cytotoxicity associated with them and hence the 
therapeutic effect or treatment efficacy to toxicity should 
always be monitored and modulated20-24. In vitro and in 
vivo, studies have been conducted to asses this modulation. 
It was identified that larger surface areas of treatments 
with nanoparticles could result in heightened and severe 
cytotoxicity. Nanoparticles used in cancer treatment in rats 
showed that it caused lung tumors as a side effect-the 
cytotoxicity. Smaller nanoparticles hence are considered 
more toxic than an equivalent chemical compound. Hence 
cytotoxicity has to be managed.  
Managing Cytotoxicity 
Han et al., analyze combination cancer therapy in the form 
of multiple anticancer agents delivered via a nanomicelle 
amphiphilic dendrimer AmD. This combination cancer 
therapy with nanotechnology form of delivery was 
observed to offer reduced cytotoxicity in-vitro and 
synergistic results for the patient. In-vitro cancer activity 
was checked on MDA-MB-231 cells with 5-FU/DOX-DNM. 
The cells were treated with an application of the drug 
mixture in different amounts. The 5-Fu/DOX-DNM, DOX-
DNM, 5 Fu-DNM, free dox, and free 5-Fu were used to stain 
the cells and absorbance was measured in order to 
understand cytotoxicity. The drug release time curves 
were mapped for all the drug forms used at different pH 
levels and it was identified that Dox and 5-Fu in standalone 
forms were pH dependent, and only around pH 5.0, the 
drug was rapid release. The cytotoxicity levels of different 
formulations are presented below. 
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Figure 1: In vitro cytotoxicity of Different Formulations, (Han et al.,2) 
 
The micelle becomes positively charged at the same pH 
levels and electrostatic repulsion is created in the micelles 
as well, accelerating drug release. 5-Fu release was faster. 
The particle size of the 5-Fu/Dox was stable under normal 
pH conditions. In terms of cellular uptake after releasing it 
was identified that the 5-Fu/Dox-DNM, 5-Fu-DNM, and 
Dox-DNM showed a more rapid intake with appropriate 
intracellular concentrations compared to the free 5-Fu and 
Dox-DNM group25-29. The use of multiple dendrimeter 
enhanced cell adhesion and disruption. In-vitro cytotoxicity 
showed that there was a much lower dose of the free Dox 
and free 5-Fu as compared against non-combination 
methods of delivery. The use of the drug-loaded micelles 
resulted in negligible cytotoxicity because the cells in 
tested concentration were biocompatible. The cationic 
dendrimeters furthermore were higher than the anionic 
dendrimeters and they served to shield the positive 
charges on dendrimeter surface, hence contribution 
decreased cytotoxicity. Similar results were also observed 
in the analysis of acute in-vivo toxicity in dendrimeters in 
melamine-based vehicles of drug delivery30-33. 
Kang et al., argue the use of nanotechnology for reduction 
of cytotoxicity. “Cytotoxicity, distribution and the ability to 
cross the BBB are some of the most significant obstacles 
involved in chemotherapy for brain tumors. 
Nanotechnology has been widely exploited in drug 
delivery, with a tremendous potential for improving drug 
efficiency and efficacy”. However, the researcher notes that 
the use of nano-technology could, in fact, result in more 
cytotoxicity, and hence nano-technology use has to be 
modulated in the following ways.  
Firstly, it can be managed by managing its half-life, as this 
will decrease the amount of time that the nanoparticles 
spend in circulation or the short drug half-life can be 
extended in a targeted way to achieve treatment efficacy. 
Alternatively, cytotoxicity can be maintained by making use 
of only those compounds that are not cytotoxic. Elements 
like phospholipids, chitosan and dextran can be made use 
of in such situations. 
Conclusion 
Cytotoxicity is a serious concern when it comes to 
achieving efficient treatment plans. The very treatment 
plan for a cancer patient should not turn detrimental to 
their overall health. The issues in cytotoxicity are 
heightened in the case of aggressive concerns as well. 
Targeted deliveries and combination drug treatments are 
useful in controlling cytotoxic, but they carry a danger as 
well because all nanomedicines carry a certain amount of 
inherent toxicity. In this case, it is necessary to 
understanding how to control for cytotoxicity in treatment 
and this review focused on the different research evidence 
on modulation. 
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